Active — Not RecruitingPhase 2

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

United States26 participantsStarted 2017-11-07

Plain-language summary

This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Documentation Of Disease
✓-Histologic Documentation: Histologically proven recurrent or residual intracranial or metastatic meningioma or meningioma with extracranial spread
✓Renal

What they're measuring

Progression-free Survival at 6 Months (PFS6)

Timeframe: up to 6 months

Trial details

NCT IDNCT03279692

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-09-18

Results submitted2023-03-29

View on ClinicalTrials.gov More High Grade Meningioma trials